Abstract:BACKGROUND AIMS: The novelty of cell and gene therapies (CGTs) has introduced unique supply chain challenges and considerations not seen by chemically synthesized (small-molecule) drugs. These complexities increase during the clinical phases, where drug safety and efficacy milestones are still underdeveloped. For example, for autologous therapies such as chimeric antigen receptor T-cell therapies, in which the treatment is developed from the patient's own cells, supply chain management plays an integral role in chemistry, manufacturing and control processes. Supply chain management requires proactive planning because of the strict cold chain requirements and time sensitivity of CGTs. This research examines strategies and responses to challenges experienced by industry stakeholders (e.g., sponsors and manufacturers) during the implementation phases of clinical supply chain management. This research further evaluates the adequacy of the current regulatory framework for distribution and supply chain management of CGTs in the US.METHODS: A survey methodology was used to query subject matter experts from the biopharmaceutical industry who were familiar with the clinical supply management of CGTs in the US. The survey instrument was developed using an implementation framework and disseminated electronically to mid- and senior-level subject matter experts who had experience with clinical trials, supply chain management and CGTs.RESULTS: A total of 128 respondents accessed the survey, and 105 respondents answered at least one question. Seventy-five respondents completed the survey. Results showed that a lack of harmonization in regulations across the supply chain, limited resources, challenges with vendor management, high costs and complexities in the supply chain due to product specificity and customization proved to be impediments for the industry. In addition, the coronavirus disease 2019 pandemic had a significant impact on supply chain implementation. The results revealed that less than half of the respondents had business continuity plans in place. These challenges increased for smaller and mid-size organizations. Thirty percent of small and mid-size organizations were less prepared to scale up than larger companies.CONCLUSIONS: Suggestions from industry stakeholders were to adopt and enforce Good Distribution Practices in the US (81%), pre-plan distribution strategies with internal and external stakeholders along the supply chain and develop agile systems and robust processes end to end. Hurdles in scaling up and scaling out from the clinical to commercial phases for time- and temperature-sensitive CGT products make it difficult to predict the supply chain's long-term feasibility. Although there are initiatives to improve these impediments, such as improving industry partnerships and creating global CGT transportation standards, there are still regulatory knowledge gaps present for CGTs. Therefore, it is essential to establish a baseline and foundation for CGT supply chains extending beyond the loading dock.

Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands

Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape

Value-based payment and financing for cell and gene therapies: challenges and potential solutions

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU

Enhancing pediatric access to cell and gene therapies

Unlocking patient access to gene therapy: five key practices

Introducing biosimilar competition for cell and gene therapy products

Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity

ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

Availability and financing of CAR-T cell therapies: A cross-country comparative analysis

An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies

Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?

Marketing approvals for cell and gene therapy products in oncology: Current review of EMA and FDA approvals.

Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon

Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines